Alector (NASDAQ:ALEC) is scheduled to announce Q4 earnings results on Wednesday, February 26th, after market close. The consensus EPS Estimate is -$0.54 (-10.2% Y/Y) and the consensus Revenue Estimate ...

Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...

Alector Inc (NASDAQ:ALEC) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue ...

Alector (NASDAQ:ALEC – Get Free Report) is anticipated to post its quarterly earnings results after the market closes on ...

In a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a new 52-week low, with shares plummeting to $1.59. This significant downturn reflects a broader trend for the ...

Alector, Inc., a late-stage clinical biotechnology company, is advancing its preclinical and research pipeline focused on genetically-validated therapies for neurodegenerative diseases.

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company’s commitment to developing genetically ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...